Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Sirona Biochem Corp
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(77)
•••
Post by Pareto8020on Jan 21, 2021 9:27am
198 Views
Post# 32343416

Tick Tock SBM - Tick Tock Howard

Tick Tock SBM - Tick Tock HowardSo in just over a week SBM will be down to 4 months to meet their "anticipated" (always a qualifier with them) Milestones which include:
  • Finalize the Beijing Huaxi Pharma Co, Ltd. collaboration agreement
  • Complete an additional licensing agreement for the SGLT2 inhibitor in new markets
  • Secure non-dilutive funding through anticipated collaborations
  • Finalize Tinyi agreement
  • Complete Phase I clinical trial in China for the SGLT2 Inhibitor and advance to Phase II
  • Complete safety studies and enter clinical trial for anti-wrinkle compound
  • Develop new anti-viral compounds and advance them into preclinical studies
If they can even get 1/2 or 3/4 of those completed and CURE can properly promote those achievements then it should be a happy spring for SBM shareholders.  If not then I wouldn't want to be the CEO at the next AGM cause he will be called out for sure if they can't execute on their own goals or plans.  
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities